Skip to content

Study · Not a test of the peptide alone · 2006

7 results

Colivelin prolongs survival of an ALS model mouse.

Chiba T, Yamada M, Sasabe J, Terashita K, Aiso S, Matsuoka M, Nishimoto I

Biochemical and biophysical research communications10 Mar 2006Cited by 30 (Europe PMC)

PMID16564029 (opens in a new tab)DOI10.1016/j.bbrc.2006.02.184 (opens in a new tab)PepBankPUB-16564029
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01AnimalNot a test of Humanin aloneAnimal study (in vivo)Efficacy outcome

    In G93A-SOD1 transgenic ALS mice, intracerebroventricular Colivelin, a hybrid of ADNF and a humanin derivative, dose-dependently improved motor performance.

    In plain wordsIn ALS mice, the Colivelin hybrid peptide improved motor performance in a dose-dependent way.

    Peptide
    Humanin
    Outcome
    IncreaseMotor performance in ALS mice
    Study

    mousen: not reported in source

    G93A-SOD1 transgenic ALS mouse
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    i.c.v. injection of a synthetic hybrid peptide named Colivelin composed of ADNF and AGA-(C8R)HNG17, a potent derivative of Humanin that is a bioactive peptide with anti-Alzheimer's disease activity, dose-dependently improved motor performance

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  2. 02AnimalNot a test of Humanin aloneAnimal study (in vivo)Efficacy outcome

    In G93A-SOD1 transgenic ALS mice, intracerebroventricular Colivelin, a hybrid of ADNF and a humanin derivative, dose-dependently prolonged survival.

    In plain wordsIn ALS mice, the Colivelin hybrid peptide prolonged survival in a dose-dependent way.

    Peptide
    Humanin
    Outcome
    IncreaseSurvival of ALS mice
    Study

    mousen: not reported in source

    G93A-SOD1 transgenic ALS mouse
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    i.c.v. injection of a synthetic hybrid peptide named Colivelin composed of ADNF and AGA-(C8R)HNG17, a potent derivative of Humanin that is a bioactive peptide with anti-Alzheimer's disease activity, dose-dependently improved motor performance and prolonged survival of ALS mice

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  3. 03AnimalNot a test of Humanin aloneAnimal study (in vivo)Efficacy outcome

    In ALS mice, Colivelin increased motoneuronal survival in the spinal cord at 120 days compared with saline or ADNF.

    In plain wordsIn ALS mice, the Colivelin hybrid peptide kept more spinal cord motor neurons alive than saline or ADNF.

    Peptide
    Humanin
    Outcome
    IncreaseMotoneuronal survival in spinal cord
    Study

    mousen: not reported in source

    G93A-SOD1 transgenic ALS mouse
    Comparator
    Saline or ADNF
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Histological analysis, performed at the age of 120 days, demonstrated increased motoneuronal survival in spinal cords of Colivelin-treated mice as compared with saline- or ADNF-treated mice

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  4. 04AnimalNot a test of Colivelin aloneAnimal study (in vivo)Efficacy outcome

    In ALS mice, intracerebroventricular Colivelin dose-dependently improved motor performance.

    In plain wordsIn mice with ALS, Colivelin improved motor performance in a dose-dependent manner.

    Peptide
    Colivelin
    Outcome
    IncreaseMotor performance
    Study

    mousen: not reported in source

    ALS mice
    Outcome group
    Exercise and physical function · Nervous system and cognition

    Source sentences

    Summary
    Here, we found that i.c.v. injection of a synthetic hybrid peptide named Colivelin composed of ADNF and AGA-(C8R)HNG17, a potent derivative of Humanin that is a bioactive peptide with anti-Alzheimer's disease activity, dose-dependently improved motor performance and prolonged survival of ALS mice.

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

  5. 05AnimalNot a test of Colivelin aloneAnimal study (in vivo)Efficacy outcome

    In ALS mice, intracerebroventricular Colivelin dose-dependently prolonged survival.

    In plain wordsIn mice with ALS, Colivelin prolonged survival in a dose-dependent manner.

    Peptide
    Colivelin
    Outcome
    IncreaseSurvival
    Study

    mousen: not reported in source

    ALS mice
    Outcome group
    Mortality · Nervous system and cognition

    Source sentences

    Summary
    Here, we found that i.c.v. injection of a synthetic hybrid peptide named Colivelin composed of ADNF and AGA-(C8R)HNG17, a potent derivative of Humanin that is a bioactive peptide with anti-Alzheimer's disease activity, dose-dependently improved motor performance and prolonged survival of ALS mice.

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

  6. 06AnimalNot a test of Colivelin aloneAnimal study (in vivo)Efficacy outcome

    In ALS mice at 120 days, Colivelin increased spinal motoneuronal survival compared with saline.

    In plain wordsIn mice with ALS at 120 days, Colivelin increased spinal motor neuron survival compared with saline.

    Peptide
    Colivelin
    Outcome
    IncreaseSpinal motoneuronal survival versus saline
    Study

    mousen: not reported in source

    ALS mice
    Comparator
    saline
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Histological analysis, performed at the age of 120 days, demonstrated increased motoneuronal survival in spinal cords of Colivelin-treated mice as compared with saline- or ADNF-treated mice

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

  7. 07AnimalNot a test of Colivelin aloneAnimal study (in vivo)Efficacy outcome

    In ALS mice at 120 days, Colivelin increased spinal motoneuronal survival compared with ADNF.

    In plain wordsIn mice with ALS at 120 days, Colivelin increased spinal motor neuron survival compared with ADNF.

    Peptide
    Colivelin
    Outcome
    IncreaseSpinal motoneuronal survival versus ADNF
    Study

    mousen: not reported in source

    ALS mice
    Comparator
    ADNF
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Histological analysis, performed at the age of 120 days, demonstrated increased motoneuronal survival in spinal cords of Colivelin-treated mice as compared with saline- or ADNF-treated mice

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:32 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    13 Oct 2026, 21:44 UTC

    Study results updated

  3. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.